Literature DB >> 12003979

Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens.

Angela M Nilius1, Dena M Hensey-Rudloff, Megan A Reimann, Robert K Flamm.   

Abstract

Attempts were made to select mutants on agar media containing the new ketolide ABT-773, erythromycin or rifampicin, at concentrations above the MICs, from Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae, including erythromycin-resistant strains. ABT-773 did not select for mutants in four strains, whereas in eight strains the frequencies at 72 h were < or = 10(-9). ABT-773 MICs were 0.015-4 mg/L for mutants, except those selected from inducible Erm(A) S. aureus. Mutants selected on ABT-773 or erythromycin were cross-resistant to ABT-773, erythromycin and, sometimes, clindamycin. The susceptibility profiles indicate that different mutations were selected and that ABT-773 and erythromycin may interact with the ribosome differently.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003979     DOI: 10.1093/jac/dkf016

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  James H Jorgensen; Sharon A Crawford; M Leticia McElmeel; Cynthia G Whitney
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos; C Barau; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.